© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 5, 446-452,
March 3, 1999
© 1999 Oxford University Press
ARTICLES |
CDKN2A Variants in a Population-Based Sample of Queensland Families With Melanoma
Affiliation of authors: Queensland Institute of Medical Research, Brisbane, Australia.
Correspondence to: Nicholas Hayward, Ph.D., Queensland Institute of Medical Research, P.O. Royal Brisbane Hospital, Herston, QLD 4029, Australia (e-mail: nickH{at}qimr.edu.au).
BACKGROUND: Mutations in the CDKN2A gene confer susceptibility to cutaneous malignant melanoma (CMM); however, the population incidence of such mutations is unknown. Polymorphisms in CDKN2A have also been described, but it is not known whether they influence melanoma risk. We investigated the association of CDKN2A mutations and polymorphisms with melanoma risk in a population-based sample of families ascertained through probands with melanoma. METHODS: The 482 Queensland, Australia, families in our sample were characterized previously as having high, intermediate, or low family risk of CMM. Unrelated individuals (n = 200 families/individuals) drawn from the Australian Twin Registry served as control subjects. For individuals in the high-risk group, the entire CDKN2A gene coding region was screened for mutations by use of the polymerase chain reaction, agarose gel electrophoresis, allele-specific oligonucleotide (ASO) hybridization, and single-strand conformation polymorphism analysis. The intermediate- and low-risk families and control subjects were analyzed by ASO hybridization for a total of six recurring mutations as well as for polymorphisms at nucleotides (Nts) 442, 500, and 540. RESULTS: CDKN2A mutations were found only in the high-risk families (nine [10.3%] of 87). The prevalence of the Nt500G (guanosine) polymorphism increased linearly with increasing familial risk (two-sided P = .02) and was highest in the nine (primarily Celtic) families with CDKN2A mutations. After adjustment for ethnic origin, the relationship between risk group and the frequency of the Nt500G allele was weakened (P = .25); however, there was no relationship between ethnic origin and Nt500-polymorphism frequency among the control subjects. CONCLUSIONS: CDKN2A mutations are rare in this population (approximately 0.2% of all melanoma cases in Queensland) and appear to be associated with melanoma in only the most affected families. The Nt500G allele appears to be associated with familial risk, but this association probably reflects Celtic ancestry.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. E. Freedberg, S. H. Rigas, J. Russak, W. Gai, M. Kaplow, I. Osman, F. Turner, J. A. Randerson-Moor, A. Houghton, K. Busam, et al. Frequent p16-Independent Inactivation of p14ARF in Human Melanoma J Natl Cancer Inst, June 4, 2008; 100(11): 784 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Goldstein, S N Stacey, J H Olafsson, G F Jonsson, A Helgason, P Sulem, B Sigurgeirsson, K R Benediktsdottir, K Thorisdottir, R Ragnarsson, et al. CDKN2A mutations and melanoma risk in the Icelandic population J. Med. Genet., May 1, 2008; 45(5): 284 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani Toward a Molecular Classification of Melanoma J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M Goldstein, M. Chan, M. Harland, N. K Hayward, F. Demenais, D Timothy Bishop, E. Azizi, W. Bergman, G. Bianchi-Scarra, W. Bruno, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents J. Med. Genet., February 1, 2007; 44(2): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Muthusamy, S. Duraisamy, C. M. Bradbury, C. Hobbs, D. P. Curley, B. Nelson, and M. Bosenberg Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma Cancer Res., December 1, 2006; 66(23): 11187 - 11193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Goldstein, M. Chan, M. Harland, E. M. Gillanders, N. K. Hayward, M.-F. Avril, E. Azizi, G. Bianchi-Scarra, D. T. Bishop, B. Bressac-de Paillerets, et al. High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL. Cancer Res., October 15, 2006; 66(20): 9818 - 9828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kanetsky, T. R. Rebbeck, A. J. Hummer, S. Panossian, B. K. Armstrong, A. Kricker, L. D. Marrett, R. C. Millikan, S. B. Gruber, H. A. Culver, et al. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res., September 15, 2006; 66(18): 9330 - 9337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. James, T. Dumeni, M. S. Stark, D. L. Duffy, G. W. Montgomery, N. G. Martin, and N. K. Hayward Rapid Screening of 4000 Individuals for Germ-line Variations in the BRAF Gene Clin. Chem., September 1, 2006; 52(9): 1675 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berwick, I. Orlow, A. J. Hummer, B. K. Armstrong, A. Kricker, L. D. Marrett, R. C. Millikan, S. B. Gruber, H. Anton-Culver, R. Zanetti, et al. The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1520 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Miller and M. C. Mihm Jr. Melanoma. N. Engl. J. Med., July 6, 2006; 355(1): 51 - 65. [Full Text] [PDF]
|
|
|
|
 |
|
 C. B Begg, A. J Hummer, U. Mujumdar, B. K Armstrong, A. Kricker, L. D Marrett, R. C Millikan, S. B Gruber, H. A. Culver, R. Zanetti, et al. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma Int. J. Epidemiol., June 1, 2006; 35(3): 756 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K B Niendorf, W Goggins, G Yang, K Y Tsai, M Shennan, D W Bell, A J Sober, D Hogg, and H Tsao MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability J. Med. Genet., June 1, 2006; 43(6): 501 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Chapman, P. Harnden, P. Chambers, C. Johnston, and M. A. Knowles Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype Clin. Cancer Res., August 15, 2005; 11(16): 5740 - 5747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Puig, J. Malvehy, C. Badenas, A. Ruiz, D. Jimenez, F. Cuellar, A. Azon, U. Gonzalez, T. Castel, A. Campoy, et al. Role of the CDKN2A Locus in Patients With Multiple Primary Melanomas J. Clin. Oncol., May 1, 2005; 23(13): 3043 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J C Y Loo, A D Paterson, A Hao, M Shennan, H Peretz, Y Sidi, D Hogg, and E Yakobson Search for genetic variants associated with cutaneous malignant melanoma in the Ashkenazi Jewish population J. Med. Genet., May 1, 2005; 42(5): e30 - e30. [Full Text] [PDF]
|
|
|
|
|
|
S. Jackson, M. Harland, F. Turner, C. Taylor, P. A. Chambers, J. Randerson-Moor, A. J. Swerdlow, I. dos Santos Silva, S. Beswick, D. T. Bishop, et al. No Evidence for BRAF as a Melanoma/Nevus Susceptibility Gene Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Matichard, P Verpillat, R Meziani, B Gerard, V Descamps, E Legroux, M Burnouf, G Bertrand, F Bouscarat, A Archimbaud, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure J. Med. Genet., February 1, 2004; 41(2): e13 - 13. [Full Text] [PDF]
|
|
|
|
|
|
M. Casula, M. Colombino, M. P. Satta, A. Cossu, P. A. Ascierto, G. Bianchi-Scarra, D. Castiglia, M. Budroni, C. Rozzo, A. Manca, et al. BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study J. Clin. Oncol., January 15, 2004; 22(2): 286 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Dragani 10 Years of Mouse Cancer Modifier Loci: Human Relevance Cancer Res., June 15, 2003; 63(12): 3011 - 3018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eskandarpour, J. Hashemi, L. Kanter, U. Ringborg, A. Platz, and J. Hansson Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations J Natl Cancer Inst, June 4, 2003; 95(11): 790 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kumar and K. Hemminki Correspondence re: Zheng et al., Haplotype of Two Variants in p16 (CDKN2/MTS-1/INK4a) Exon 3 and Risk of Squamous Cell Carcinoma of the Head and Neck: a Case-Control Study. 11: 640-645, 2002 Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 71 - 71. [Full Text] [PDF]
|
|
|
|
|
|
D. T. Bishop, F. Demenais, A. M. Goldstein, W. Bergman, J. N. Bishop, B. B.-d. Paillerets, A. Chompret, P. Ghiorzo, N. Gruis, J. Hansson, et al. Geographical Variation in the Penetrance of CDKN2A Mutations for Melanoma J Natl Cancer Inst, June 19, 2002; 94(12): 894 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Orlow, P. Roy, A. Barz, R. Canchola, Y. Song, and M. Berwick Validation of Denaturing High Performance Liquid Chromatography as a Rapid Detection Method for the Identification of Human INK4A Gene Mutations J. Mol. Diagn., November 1, 2001; 3(4): 158 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Berggren, R. Kumar, G. Steineck, M. Ichiba, and K. Hemminki Ethnic variation in genotype frequencies of a p53 intron 7 polymorphism Mutagenesis, November 1, 2001; 16(6): 475 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsao, X. Zhang, K. Kwitkiwski, D. M. Finkelstein, A. J. Sober, and F. G. Haluska Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma Arch Dermatol, September 1, 2000; 136(9): 1118 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Borg, T. Sandberg, K. Nilsson, O. Johannsson, M. Klinker, A. Masback, J. Westerdahl, H. Olsson, and C. Ingvar High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families J Natl Cancer Inst, August 2, 2000; 92(15): 1260 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Berggren, K. Hemminki, and G. Steineck p53 intron 7 polymorphisms in urinary bladder cancer patients and controls Mutagenesis, January 1, 2000; 15(1): 57 - 60. [Abstract] [Full Text] [PDF]
|
|